Voyager Therapeutics, Inc. (VYGR)

Market Cap	412.85M
Revenue (ttm)	119.04M
Net Income (ttm)	-3.04M
Shares Out	54.39M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	335,985
Open	7.82
Previous Close	7.86
Day's Range	7.55 - 7.83
52-Week Range	6.06 - 11.72
Beta	1.04
Analysts	Strong Buy
Price Target	18.00 (+137.15%)
Earnings Date	Aug 1, 2024

About VYGR

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 11, 2015
• Employees: 162
• Stock Exchange: NASDAQ
• Ticker Symbol: VYGR

Analyst Forecast

According to 6 analysts, the average rating for VYGR stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 137.15% from the latest price.

Price Target

$18.0

(137.15% upside)

Analyst Consensus: Strong Buy